To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

View sample alert

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 31 October 2022
Document: Freedom of Information request (FOI 22/1032)- attachment (PDF)

Found: As in psoriasis, patients with PsA are reported to be at increased risk for occlusive vascular diseases

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 7 November 2022
Document: Freedom of Information request (FOI 22/1025) - attachment 3 (PDF)

Found: Haemostasis is a normal physiological process following damage of the vascular system.

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 7 November 2022
Document: Freedom of Information request (FOI 22/1025) - attachment 2 (PDF)

Found: Introduction Key Points: • Thromboembolic disorders are the single largest cause of disease and death

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 14 November 2022
Document: Freedom of Information request (FOI 22/951) - attachment 1 (PDF)

Found: hypomotility disorders NEC Constipation 3 0 Gastrooesophageal reflux disease 4 0

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 28 November 2022
Document: Freedom of Information request (FOI 22/1107) - attachment 2 (PDF)

Found: Renal disorder 1 0 Renal vascular and ischaemic conditions Renal vasculitis 1 0

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 28 November 2022
Document: Freedom of Information request (FOI 22/1092) - attachment 2 (PDF)

Found: vitreous haemorrhages and vascular disorders Vitreous haemorrhage 1 0 Colour blindness (incl

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 28 November 2022
Document: Freedom of Information request (FOI 22/1107) - attachment 7 (PDF)

Found: corneal bleeding and vascular disorders Conjunctival haemorrhage 1 0 Eyelid movement disorders

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 29 August 2022
Document: FOI 22/875 - attachment 5 (PDF)

Found: lacrimal infections, irritations and inflammations Eyelid oedema 1 0 Ocular bleeding and vascular

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 29 August 2022
Document: FOI 22/755_PDF - attachment 2 (PDF)

Found: It is a worldwide disease that affects approximately 300,000 people in Europe and 350,000 people in the

Non-Departmental Publication (Transparency)
Medicines and Healthcare products Regulatory Agency

Jan. 17 2024

Source Page: Freedom of Information responses from the MHRA - week commencing 22 August 2022
Document: FOI 22/877 - attachment (PDF)

Found: and thy roid disease.